Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacteremia
Staphylococcus Aureus
Staphylococcus Aureus Bacteremia
Bacteremia Staph
Bacteremia Due to Staphylococcus Aureus

Interventions

BIOLOGICAL: AP-SA02
OTHER: Placebo

Sponsor

Armata Pharmaceuticals, Inc.

Collaborators

[object Object]